Evaluating ART alternatives for people
living with HIV

The ELDORADO project aims to assess the long-term toxicity of dolutegravir and to compare its efficacy and tolerability with those of doravirine in first-line antiretroviral treatment for people living with HIV, particularly in sub-Saharan Africa.

Countries involved

The ELDORADO project is conducted in 19 clinical sites over 6 countries
(Brazil, Cameroon, Côte d’Ivoire, France, Mozambique and Thailand).

The Objectives of the ELDORADO
Project

ELDORADO is an international, multicenter, clinical research project that aims at evaluating the toxicity of dolutegravir-based antiretroviral treatment and investigates doravirine as a potentially safer and equally virologically effective first-line alternative for PLHIV.

ELDORADO includes a randomized clinical trial, conducted across six countries on four continents: Cameroon, Côte d’Ivoire, Mozambique, Brazil, Thailand, and France, that will compare dolutegravir and doravirine in terms of:

Virologic efficacy
Safety (including metabolic, cardiac, and hepatic outcomes)
Mental health and quality of life

This interdisciplinary project aims to generate high-quality evidence to inform global and national HIV treatment guidelines.

ELDORADO is supported by the Global Health EDCTP3 Joint Undertaking, Inserm-ANRS MIE, and MSD.

45bb2f84ea6d4eeee79bf65f757bce0e2b576082

dc9cb650bf969198e81bddbf23bb605921a2c1f9 (1)

9597650aa889223dbdfcefc09cf858cc35e71ecb

980d683bcd4abd3a0c2054a2146415381a76f41f

Work Packages

The Eldorado project is organized into highly interactive Work Packages (WPs) to ensure optimal implementation of all activities, from project and trial coordination to capacity building before and after the trials, including embedded studies, and especially the dissemination and utilization of results among all stakeholders.